Clinical Trial: ALDH1B1 participates in the research on the pathogenesis of inflammatory demyelinating diseases in the central nervous system by regulating Th17 differentiation through mitochondrial metabolic reprogramming (China)

Posted On: 2026-09-15

China, Sept. 15 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'ALDH1B1 participates in the research on the pathogenesis of inflammatory demyelinating diseases in the central nervous system by regulating Th17 differentiation through mitochondrial metabolic reprogramming'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132401

Registration Time: 2026/09/14

Type: Observational study

Primary Sponsor: The Affiliated Hospital of Xuzhou Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=335704

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: ALDH1B1 participates in the research on the pathogenesis of inflammatory demyelinating diseases in the central nervous system by regulating Th17 differentiation through mitochondrial metabolic reprogramming (China)